Last reviewed · How we verify
COVID-19 convalescent plasma
COVID-19 convalescent plasma is a treatment that uses antibodies from recovered patients to help the body fight off the SARS-CoV-2 virus.
COVID-19 convalescent plasma is a treatment that uses antibodies from recovered patients to help the body fight off the SARS-CoV-2 virus. Used for Treatment of COVID-19 in patients with severe or critical illness.
At a glance
| Generic name | COVID-19 convalescent plasma |
|---|---|
| Also known as | CCP |
| Sponsor | Lifefactors Zona Franca, SAS |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Convalescent plasma contains antibodies that have been shown to neutralize the SARS-CoV-2 virus. These antibodies can help to reduce the severity and duration of COVID-19 symptoms, and may also help to prevent severe illness and death.
Approved indications
- Treatment of COVID-19 in patients with severe or critical illness
Common side effects
- Thrombosis
- Allergic reactions
Key clinical trials
- Study Testing Convalescent Plasma vs Best Supportive Care (PHASE1)
- Intermediate IND Severe Illness COVID-19 CP (PHASE1)
- Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
- Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients (PHASE2)
- Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection (NA)
- Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation (PHASE2)
- Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-19 convalescent plasma CI brief — competitive landscape report
- COVID-19 convalescent plasma updates RSS · CI watch RSS
- Lifefactors Zona Franca, SAS portfolio CI